ARVN Stock Forecast: Arvinas, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$6.46
−4.15% on the day

The 15 Wall Street analysts covering Arvinas, Inc. hold a median 12-month price target of $13 — +101.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 74 of 100 as at 21 Nov 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$441.4M
Ticker Nerd rank
74/ 100
Median analyst target
$13
Analysts covering
15
Revenue$249.7M+1014.7% y/y
Operating income$164.1M
Net income$169.4M
Free cash flow−$48.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.3%
1M
−15.7%
YTD
−45.5%
1Y
−41.4%
From 52W high
−53.3%
From 52W low
+0.8%
$6
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Arvinas, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
74/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
93
Revisions
77
Issuance
77
Volatility
73
Value
51
Growth
45
Momentum
42
Accruals
30

Quality (93): The business earns solid, repeatable profits on what it owns.

Accruals (30): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ARVN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ARVN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Jan 26Apr 26Jul 26Oct 26ARVNHigh $21Median $13Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
7
Buy
8
Hold
0
Sell
$8
Low
$13
Median
$21
High

The green dot is the last close — the median target sits +101.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
3 Nov 2026HC Wainwright & Co.MaintainsBuy$18 → $13
10 Aug 2026CitigroupMaintainsBuy$24 → $21
10 Aug 2026Evercore ISI GroupMaintainsOutperform$19 → $14
5 Aug 2026WedbushMaintainsNeutral$11 → $12
5 Aug 2026Wells FargoDowngradeEqual-Weight$15 → $11
4 Aug 2026BTIGReiteratesBuy$18
3 June 2026Stephens & Co.ReiteratesOverweight$18
13 May 2026BarclaysMaintainsOverweight—
13 May 2026BTIGMaintainsBuy—
4 May 2026CitigroupMaintainsBuy—
19 Mar 2026BTIGMaintainsBuy—
19 Mar 2026CitigroupMaintainsBuy—
5 Mar 2026CitigroupMaintainsBuy—
25 Feb 2026Evercore ISI GroupMaintainsOutperform—
25 Feb 2026Piper SandlerReiteratesOverweight—
25 Feb 2026WedbushMaintainsNeutral—
6 Jan 2026CitigroupUpgradeBuy—
17 Dec 2025BarclaysMaintainsOverweight—
10 Nov 2025Stephens & Co.MaintainsOverweight—
6 Nov 2025BarclaysMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ARVN.

Market Radar

This page is one stock. Monday covers all of them.

ARVN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ARVN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Arvinas, Inc. returned −41.4% against +6.9% for the S&P 500, dividends included.

ARVN vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120Jan 26Apr 26Jul 26Oct 26ARVNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ARVN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
6
Analysts cutting
2
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
1.6×

Cheaper than 54% of US stocks

Price / book
0.9×

Cheaper than 76% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
−10.1%

Higher than 26% of US stocks

Net margin
—
Returns & dividend
Return on equity
−1.8%

Higher than 43% of US stocks

Return on assets
−2.4%

Higher than 36% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Arvinas, Inc. has a market value of $441.4M.

  • Revenue in the twelve months to 30 June 2026: $316.7M. The latest quarter grew 1014.7% year on year.

  • Net income over the same four quarters: $9.3M, a 2.9% net margin.

  • Diluted earnings per share, trailing twelve months: $0.10.

  • Free cash flow in the twelve months to 30 June 2026: −$208.8M.

  • Shares outstanding: 65.3M.

  • Arvinas, Inc. employs 246 people — $1.3M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

ARVN and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ARVNArvinas, Inc.$441.4M74
IRLAIRulya Therapeutics, Inc.$432.4M33
TECXTectonic Therapeutic, Inc.$413.5M44
INDPIndaptus Therapeutics, Inc.$433.1M25
CRMDCorMedix, Inc.$410.8M63
OCSOculis Holding AG$435.8M30
OVIDOvid Therapeutics, Inc.$410.6M47

Take a look at ARVN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Arvinas, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ARVN

What is the ARVN stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Arvinas, Inc. have a median 12-month price target of $13, with estimates ranging from $8 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ARVN stock a buy right now?

Of the 15 analysts covering Arvinas, Inc., 7 rate it a Buy, 8 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Arvinas, Inc. 74 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ARVN?

As at 21 Nov 2026, Arvinas, Inc. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (93 of 100).

Will ARVN stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +101.2% from the last close, and Ticker Nerd's factor model ranks Arvinas, Inc. 74 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ARVN stock forecast for 2030?

No analyst covering Arvinas, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARVN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $21 over the next 12 months.

How has ARVN stock performed over the past year?

Arvinas, Inc. returned -41.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Arvinas, Inc. do?

Arvinas, Inc. is a clinical-stage biotechnology company focused on targeted protein degradation. The company develops therapies designed to harness the body’s natural protein disposal system to selectively degrade disease-causing proteins, using its proprietary PROTAC platform.

Company

About Arvinas, Inc.

Arvinas, Inc. is a clinical-stage biotechnology company focused on targeted protein degradation. The company develops therapies designed to harness the body’s natural protein disposal system to selectively degrade disease-causing proteins, using its proprietary PROTAC platform. Its current pipeline includes investigational programs in oncology and neuroscience, with candidates aimed at hormone-driven cancers, mutated cancers, lymphoma, and neurodegenerative disorders. Arvinas also advances collaboration-based programs alongside wholly owned assets, reflecting a business model centered on drug discovery, clinical development, and strategic partnerships. Headquartered in New Haven, Connecticut, Arvinas plays a notable role in the biopharmaceutical market as a developer of next-generation medicines intended to address difficult-to-treat diseases through a differentiated protein-degradation approach.

CEO Dr. Randy Teel Ph.D. · 246 employees · United States · https://www.arvinas.com